# TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC

> **NCT07658833** · — · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 120 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **PROCEDURE:** TACE (transarterial chemoembolization) combined with targeted/immunotherapy

## Key facts

- **NCT ID:** NCT07658833
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07658833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07658833, "TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07658833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*